Table of Content

  1. Introduction
    • Definition of Tumor Infiltrating Lymphocytes Market
    • Scope of the Report
  2. Methodology
    • Executive Summary
    • Market Overview
    • Market Definition and Segmentation
  3. Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
    • Porter's Five Forces Analysis
    • PESTEL Analysis
  4. Tumor Infiltrating Lymphocytes Market, By Types
    • Cervical Cancer
    • Ovarian Cancer
    • Kidney Cancer
    • Gastrointestinal Cancer
    • Head and Neck Cancers
  5. Tumor Infiltrating Lymphocytes Market, By Component
    • T-Cells
    • B-Cells
    • Natural Killer Cells
  6. Tumor Infiltrating Lymphocytes Market, By Anatomy
    • CD3
    • CD8
    • CD16
    • CD56
    • CD4
    • CD57
    • CD169
    • CD68
    • FOXP3
  7. Tumor Infiltrating Lymphocytes Market, By End User
    • Hospitals
    • Cancer Research Centers
    • Clinics
  8. Tumor Infiltrating Lymphocytes Market, By Geography
    • North America
      • United States
      • Canada
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Italy
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • Saudi Arabia
      • United Arab Emirates
      • South Africa
      • Rest of Middle East & Africa
  9. Competitive Landscape
  10. Company Profiles
    • Autolus Therapeutics (U.K.)
      • Company Overview
      • Product Portfolio and Description
      • Key Highlights
      • Financial Overview
    • Bellicum Pharmaceuticals, Inc. (U.S.)
    • Eli Lilly and Company (U.S.)
    • Novartis AG (Switzerland)
    • Oxford Biomedica (U.K.)
    • Pfizer Inc. (U.S.)
    • Precision Biosciences (U.S.)
    • Seeking Alpha (U.S.)
    • bluebird bio, Inc. (U.S.)
    • TCR² Therapeutics (U.S.)
    • Fate Therapeutics (U.S.)
    • Merck KGaA (Germany)
  11. Conclusion and Future Outlook
  12. Appendix
    • Research Methodology
    • About the Pharmanucleus
  13. Disclaimer


Why Choose Us

Inclusion of Pre-clinical Molecules

Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!

Start-up
Profiling

One of our marquee services We profile relevant start-up companies in the market.

KOL
Insight's

Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.

Specialized in Healthcare

Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.